Company intelligence / Profile preview

Oneness Biotech Co., Ltd.

Ownership: Private
Employees: ~43
Development stage: Other

Overview

Lead product Fespixon® (ON101) for diabetic foot ulcers has received marketing approval in Taiwan and is in Phase III trials in the US. FB825 for atopic dermatitis has been licensed to LEO Pharma. The company has multiple other candidates in various stages of development.

Therapeutic areas: PulmonologyMetabolic DisordersEndocrinologyImmunologyDermatologyOncologyInfectious Diseases
Modalities: Small moleculesMonoclonal antibodiesBotanical drugs
Industry: Biotech

Drug pipeline

16 assets

Fespixon

15 more assets in the full pipeline.

Partnerships

LEO Pharma (for FB825)

Beyond the preview

Go deeper on Oneness Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oneness Biotech Co., Ltd..